Back to top
more

Cardiol Therapeutics (CRDL)

(Real Time Quote from BATS)

$1.10 USD

1.10
3,699,431

-0.25 (-18.52%)

Updated Aug 6, 2025 02:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (83 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sundeep Ganoria headshot

Cardiol Therapeutics Stock: Is Cannabis Potential Priced In?

by Sundeep Ganoria

Cardiol Therapeutics shows promise with its CBD-based heart therapy, but a lack of approved drugs and a narrow pipeline raise red flags for cautious investors.

Zacks Equity Research

Is Cogent Biosciences (COGT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Cogent Biosciences, Inc. (COGT) and Cardiol Therapeutics Inc. (CRDL) have performed compared to their sector so far this year.

Zacks Equity Research

Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol

by Zacks Equity Research

Corcept, Amneal, Dyne, Nektar and Cardiol have been highlighted in this Industry Outlook article.

Kinjel Shah headshot

5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

by Kinjel Shah

Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio.

Zacks Equity Research

Are Medical Stocks Lagging Cardiol Therapeutics (CRDL) This Year?

by Zacks Equity Research

Here is how Cardiol Therapeutics Inc. (CRDL) and Catalent (CTLT) have performed compared to their sector so far this year.

Zacks Equity Research

Cardiol Therapeutics (CRDL) Upgraded to Buy: Here's Why

by Zacks Equity Research

Cardiol Therapeutics (CRDL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Kinjel Shah headshot

5 Small Drug Stocks to Buy From a Recovering Industry

by Kinjel Shah

Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.

Zacks Equity Research

Here's Why You May Invest in Cardiol Therapeutics (CRDL) Stock

by Zacks Equity Research

Here we discuss some reasons why investing in Cardiol Therapeutics (CRDL) stock now may turn out to be a prudent move.

Zacks Equity Research

Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)?

by Zacks Equity Research

Here we discuss why investing in Aurinia Pharmaceuticals (AUPH) stock now may be a prudent move.

Zacks Equity Research

Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Cardiol Therapeutics Inc. (CRDL) and DiaMedica Therapeutics, Inc. (DMAC) have performed compared to their sector so far this year.

Zacks Equity Research

Zacks Industry Outlook Highlights Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics

by Zacks Equity Research

Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics are part of the Zacks Industry Outlook article.

Kinjel Shah headshot

5 Stocks to Buy as Drug Industry Displays Strong Fundamentals

by Kinjel Shah

Innovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one's portfolio.

Zacks Equity Research

Cardiol Therapeutics Inc. (CRDL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Cardiol Therapeutics Inc. (CRDL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

Cardiol Therapeutics Inc. (CRDL) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Cardiol Therapeutics Inc. (CRDL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?

by Zacks Equity Research

Here is how ANI Pharmaceuticals (ANIP) and Cardiol Therapeutics Inc. (CRDL) have performed compared to their sector so far this year.

Zacks Equity Research

Here's Why Cardiol Therapeutics Inc. (CRDL) Could be Great Choice for a Bottom Fisher

by Zacks Equity Research

Cardiol Therapeutics Inc. (CRDL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks Equity Research

Cardiol Therapeutics Inc. (CRDL) Could Find Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

Cardiol Therapeutics Inc. (CRDL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.